Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Eltrombopag (Primary)
- Indications Thrombocytopenia; Wiskott-Aldrich syndrome
- Focus Therapeutic Use
- 31 Jan 2017 Planned End Date changed from 1 Jun 2013 to 1 Jun 2020.
- 31 Jan 2017 Planned primary completion date changed from 1 Jun 2013 to 1 May 2019.
- 31 Jan 2017 Status changed from Recruiting to active, no longer recruiting.